Tyra reports positive SURF302 data: 79% ORR, 57% CR at 60mg in FGFR3-altered NMIBC

Tyra Biosciences, Inc.

SURF302: 60mg QD ORR 79% (11/14), CR 57% (8/14) at 3 months; 50mg ORR 67%, CR 33%.
Safety: no Grade 4/5 TEAEs; Grade 3 treatment-related AEs in 4.5% (2/44), none at 60mg; no dose reductions at 60mg.
Exposure-response: ORR 86% above AUC 2500 vs 58% below; supports 60mg adjuvant, 70mg cohort planned for ablative.
Plans: complete 60mg enrollment, initiate 70mg cohort, engage health authorities; registrational adjuvant study expected 2027.
Also: SURF303 first patient CR at 3 months; BEACH301 cleared fifth dose level in achondroplasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.